Alison Kurimchak
- Hematology top 10%
- Multiple Myeloma Research and Treatments 4
-
- Cancer-related Molecular Pathways 8
- Peptidase Inhibition and Analysis 3
-
- Ubiquitin and proteasome pathways 13
- Protein Degradation and Inhibitors 4
- Epigenetics and DNA Methylation 2
-
- Microtubule and mitosis dynamics 7
-
- Genetic factors in colorectal cancer 2
- Co-authors
- Xavier GrañaJames S. DuncanJonathan ChernoffKelly DuncanClaude SheltonJudit GarrigaDenise C. ConnollyShane W. O’Brien
- Cited by
- HematologyOncologyMolecular Biology
- Journals
- Journal of Biological Chemistry (5 papers)Cell Reports (2 papers)Science Signaling (2 papers)
- Partner nations
- United StatesRussiaSweden
In The Last Decade
Alison Kurimchak
21 papers receiving 539 citations
Peers
Comparison fields: 5 of 65
- Hematology 81
- Oncology 186
- Molecular Biology 439
- Cancer Research 74
- Cell Biology 68
Countries citing papers authored by Alison Kurimchak
This map shows the geographic impact of Alison Kurimchak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Kurimchak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Kurimchak more than expected).
Fields of papers citing papers by Alison Kurimchak
This network shows the impact of papers produced by Alison Kurimchak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Kurimchak. The network helps show where Alison Kurimchak may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Alison Kurimchak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 3 | |
| 5 | 2023 | 2 | |
| 6 | 2022 | 27 | |
| 7 | 2022 | 64 | |
| 8 | 2022 | 6 | |
| 9 | 2021 | 23 | |
| 10 | 2020 | 19 | |
| 11 | 2020 | 18 | |
| 12 | 2019 | 25 | |
| 13 | 2019 | 22 | |
| 14 | 2016 | 143 | |
| 15 | 2014 | 30 | |
| 16 | 2013 | 23 | |
| 17 | 2012 | 43 | |
| 18 | 2012 | 25 | |
| 19 | 2009 | 11 | |
| 20 | 2008 | 16 |
About Alison Kurimchak
Alison Kurimchak is a scholar working on Oncology, Cell Biology and Hematology, having authored 21 papers that have together received 541 indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (13 papers), Cancer-related Molecular Pathways (8 papers), Microtubule and mitosis dynamics (7 papers), Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (4 papers), Peptidase Inhibition and Analysis (3 papers), Epigenetics and DNA Methylation (2 papers) and Genetic factors in colorectal cancer (2 papers). The work is most often cited by research in Hematology (81 citations), Oncology (186 citations) and Molecular Biology (439 citations). Alison Kurimchak has collaborated with scholars based in United States, Russia and Sweden. Frequent co-authors include Xavier Graña, James S. Duncan, Jonathan Chernoff, Kelly Duncan, Claude Shelton, Judit Garriga, Denise C. Connolly, Shane W. O’Brien, Elena Sotillo and Rashid Gabbasov. Their work appears in journals such as Journal of Biological Chemistry, Cell Reports, Science Signaling, Gene and Genes & Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.